Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of pembrolizumab plus pemetrexed and platinum chemotherapy in EGFR-mutated TKI-resistant metastatic nonsquamous NSCLC
MOH_2018-05-07_002364Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Apr 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) and bronchial carcinoma comparing Pembrolizumab + pemetrexed + platinum chemotherapy with Placebo + pemetrexed + platinum chemotherapy (2 arms). Started Apr 2018; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)bronchial carcinoma
Beyond the preview
Go deeper on MOH_2018-05-07_002364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-05-07_002364.